Related Experiment Video

Updated: Jun 17, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC

Giulia Notini1,2,3,4,5, Barbara Galbardi1, Giulia Viale1,2

  • 1Medical Oncology Department, IRCCS San Raffaele Hospital, Milan, Italy.

NPJ Precision Oncology
|June 15, 2026
PubMed

Insights

Trop2 antibody-drug conjugates (ADCs) target epithelial cancers. This study reveals TACSTD2 expression is epigenetically controlled and linked to tumor microenvironment, but antigen levels alone don't predict ADC success.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Trop2-directed antibody-drug conjugates (ADCs) demonstrate efficacy in epithelial cancers.
  • Understanding Trop2 (TACSTD2) expression determinants is crucial for optimizing ADC therapy.

Purpose of the Study:

  • To comprehensively map TACSTD2 expression, regulation, and functional associations in solid tumors and normal tissues.
  • To investigate the relationship between TACSTD2 expression and factors influencing ADC efficacy and toxicity.

Main Methods:

  • Integrated analysis of bulk and single-cell transcriptomic data from over 20,000 samples (TCGA, GTEx, public atlases).
  • Exploration of genomic alterations, DNA methylation, and co-expression networks related to TACSTD2.

Main Results:

  • TACSTD2 expression is restricted to epithelial cells, enriched in tumors, and epigenetically regulated by DNA methylation.
  • Expression correlates with tumor microenvironment pathways, including barrier integrity and immune interactions.
  • Modest, context-dependent co-expression with ADC-processing and payload sensitivity genes was observed.

Conclusions:

  • Epigenetic factors, not just genomic alterations, predominantly control TACSTD2 expression.
  • TACSTD2 expression influences tumor microenvironment and immune responses, suggesting potential for combination therapies.
  • Tumor antigen abundance alone is insufficient to predict the efficacy or toxicity of Trop2-directed ADCs across different cancer types.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...